Clinical Trials Sponsored by CSL Limited

Total 3522 results

CSL Behring

Completed

Effects of CSL324 in the Lung After Segmental Challenge

Healthy Volunteers

Germany
CSL Behring

Completed

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Hereditary Angioedema

United States, Germany, Japan, Hungary, Canada, Netherlands, Israel
CSL Behring

Completed

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema

Canada, Australia, Germany, United States, Israel
CSL Behring

Completed

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

Healthy

Australia
CSL Behring

Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Antibody-mediated Rejection

United States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
CSL Behring

Completed

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Acute Myocardial Infarction

United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
CSL Behring

Terminated

Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)

Chronic Inflammatory Demyelinating Polyneuropathy

France
CSL Behring

Withdrawn

CSL324 in COVID-19

Coronavirus Disease 2019 (COVID-19)
CSL Behring

Completed

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Acute Myocardial Infarction | Moderate Renal Impairment

United States, Germany, Hungary, Israel, Netherlands
CSL Behring

Completed

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Japan, Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
CSL Behring

Completed

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Primary Immune Deficiency | Secondary Immune Deficiency

Canada
CSL Behring

Completed

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

Acute Myocardial Infarction

Germany, United Kingdom
CSL Behring

Completed

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Hereditary Angioedema Types I and II

Bulgaria, Hungary, Poland, Romania
CSL Behring

Completed

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Emphysema | Alpha 1-proteinase Inhibitor Deficiency

Australia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
CSL Behring

Completed

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema | Alpha1-proteinase Inhibitor Deficiency

Australia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
CSL Behring

Completed

Health Related Quality of Life of Youth and Young Adults With Hemophilia A

Hemophilia A

Canada
CSL Behring

Completed

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Multifocal Motor Neuropathy (MMN)

Switzerland, Italy, United Kingdom
CSL Behring

Completed

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Hereditary Angioedema Types I and II

Germany
CSL Behring

Completed

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States, Spain
CSL Behring

Completed

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Cystic Fibrosis

Bulgaria, Hungary, Poland, United Kingdom
CSL Behring

Completed

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Von Willebrand Disease

Canada
CSL Behring

Completed

Retrospective Chart Review of Subcutaneous IgG Use in Infants

Primary Immune Deficiency

United States
CSL Behring
Parexel

Completed

Study of Biostate® in Children With Von Willebrand Disease

Von Willebrand Disease

Ukraine, Lebanon, Germany, Belarus, Georgia, Guatemala
CSL Behring
Parexel

Completed

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Poland, Russian Federation, Ukraine
CSL Behring
Parexel

Completed

Study of Biostate® in Children With Hemophilia A

Hemophilia A

Ukraine, Lebanon, Belarus, Georgia, Guatemala, Mexico
Isala
CSL Behring

Completed

Haemocomplettan® P During Elective Complex Cardiac Surgery

Fibrinogen Deficiency in Complex Cardiac Surgery

Netherlands
CSL Behring
Parexel

Completed

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Hemophilia A

Bulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
CSL Behring
Parexel

Completed

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Hereditary Angioedema Types I and II

United States, Germany
Bloodworks
CSL Behring

Completed

Joint Health Study

Hemophilia B

United States
Mayo Clinic
CSL Behring

Completed

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Bleeding | Blood Loss, Surgical | Cardiovascular Surgical Procedures | Prothrombin Complex Concentrates | Fresh Frozen Plasma

United States
CSL Behring
Kaiser Permanente

Completed

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Hemorrhage

United States
Georgetown University
CSL Behring

Unknown

IVIG Treatment in Systemic Sclerosis

Systemic Sclerosis | Diffuse Scleroderma

United States
Rigshospitalet, Denmark
CSL Behring

Completed

Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage

Trauma | Haemorrhage

Denmark
Yale University
CSL Behring

Withdrawn

A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH) (PERFECT PPH)

Postpartum Hemorrhage
Emory University
CSL Behring

Terminated

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT)

Coronary Artery Disease | Heart Valve Disease

United States
Duke University
CSL Behring

Completed

Open Label Use Of RiaStap During Aortic Reconstruction

Coagulopathic Bleeding

United States
CSL Behring
ICON Clinical Research

Terminated

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE)

Antibody-mediated Rejection

Korea, Republic of, United States, New Zealand, Spain, Taiwan, Netherlands, Australia, France, Canada, Belgium, Czechia, Hungary, Sweden, Austria, Germany
NYU Langone Health
CSL Behring

Completed

C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

Antibody Mediated Rejection of Kidney Transplant

United States
St. Louis University
CSL Behring

Terminated

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (SIMM)

Myasthenia Gravis

United States
Tampere University Hospital
CSL Behring

Completed

Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage

Aneurysmatic Subarachnoid Haemorrhage

Finland
University College, London
CSL Behring

Unknown

CSL Behring Sclero XIII

Systemic Sclerosis

United Kingdom
Virginia Commonwealth University
CSL Behring

Completed

Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia

Hemophilia A | Hemophilia B | Vitamin D Deficiency

United States
CSL Behring
Chiltern International Inc.

Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

Includes: Hereditary Angioedema

United States, Denmark, Germany, Switzerland
University of Alberta
CSL Behring

Completed

A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) (SCIG-MG)

Myasthenia Gravis

Canada
CSL Behring
ICON Clinical Research

Completed

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Polyradiculoneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy

United States, Australia, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Spain, United Kingdom

Clinical Trials Sponsored by CSL Limited

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations